Compumedics (ASX:CMP) said the last financial year laid a stronger more scalable business model for FY26 and beyond with record sales orders of $63.4 million, up 22% on FY24. EBITDA increased to ~$3m, ...
Compumedics delivers breakout performance in FY25 with record revenue and sales orders, a return to profitability, and accelerating growth in the US and SaaS segments. Compumedics (ASX:CMP) said the ...